Recombinant Human SIGLEC5 protein (Fc Chimera) (ab221413)

Submit a review Submit a question

Description

  • Product name

    Recombinant Human SIGLEC5 protein (Fc Chimera)

  • Purity

    > 95 % SDS-PAGE.

  • Endotoxin level

    < 1.000 Eu/µg

  • Expression system

    HEK 293 cells

  • Accession

    O15389

  • Protein length

    Protein fragment

  • Animal free

    No

  • Nature

    Recombinant

    • Species

      Human

    • Sequence

      EKPVYELQVQKSVTVQEGLCVLVPCSFSYPWRSWYSSPPLYVYWFRDGEI PYYAEVVATNNPDRRVKPETQGRFRLLGDVQKKNCSLSIGDARMEDTGSY FFRVERGRDVKYSYQQNKLNLEVTALIEKPDIHFLEPLESGRPTRLSCSL PGSCEAGPPLTFSWTGNALSPLDPETTRSSELTLTPRPEDHGTNLTCQMK RQGAQVTTERTVQLNVSYAPQTITIFRNGIALEILQNTSYLPVLEGQALR LLCDAPSNPPAHLSWFQGSPALNATPISNTGILELRRVRSAEEGGFTCRA QHPLGFLQIFLNLSVYSLPQLLGPSCSWEAEGLHCRCSFRARPAPSLCWR LEEKPLEGNSSQGSFKVNSSSAGPWANSSLILHGGLSSDLKVSCKAWNIY GSQSGSVLLLQGRSNLGT

    • Predicted molecular weight

      73 kDa including tags

    • Amino acids

      17 to 434

    • Additional sequence information

      Fused with a human IgG1 Fc tag (Pro 100 - Lys 330; P01857) at the C-terminus (AAH29896).

Specifications

Our Abpromise guarantee covers the use of ab221413 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    SDS-PAGE

  • Form

    Lyophilised
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Store at -20°C or -80°C. Avoid freeze / thaw cycle.

    pH: 7.50
    Constituents: 0.61% Tris, 0.75% Glycine, 5% Trehalose, Sodium chloride, L-Arginine

    Lyophilized from 0.22 µm filtered solution.

  • Reconstitution
    It is recommended to reconstitute the lyophilized product in sterile deionized water to a final concentration of 1 mg/ml. Solubilize for 30 to 60 minutes at room temperature with occasional gentle mixing. Carrier protein (0.1% HSA or BSA) is strongly recommended for further dilution and long term storage.

General Info

  • Alternative names

    • CD170
    • CD170 antigen
    • CD33 antigen-like 2
    • CD33L2
    • mSiglec-F
    • OB-binding protein 2
    • OB-BP2
    • OBBP2
    • Obesity-binding protein 2
    • Sialic acid binding Ig-like lectin 5
    • Sialic acid binding immunoglobulin-like lectin 5
    • Sialic acid-binding Ig-like lectin 5
    • Sialic acid-binding Ig-like lectin F
    • SIGL5_HUMAN
    • Siglec-5
    • Siglec-F variant
    • Siglec5
    • Siglecf
    see all

  • Function

    Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Binds equally to alpha-2,3-linked and alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface.

  • Tissue specificity

    Expressed by monocytic/myeloid lineage cells. Found at high levels in peripheral blood leukocytes, spleen, bone marrow and at lower levels in lymph node, lung, appendix, placenta, pancreas and thymus. Expressed by monocytes and neutrophils but absent from leukemic cell lines representing early stages of myelomonocytic differentiation.

  • Sequence similarities

    Belongs to the immunoglobulin superfamily. SIGLEC (sialic acid binding Ig-like lectin) family.
    Contains 2 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 Ig-like V-type (immunoglobulin-like) domain.

  • Domain

    Contains 1 copy of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is involved in modulation of cellular responses. The phosphorylated ITIM motif can bind the SH2 domain of several SH2-containing phosphatases.

  • Cellular localization

    Membrane.
  • Information by UniProt

Images

  • SDS-PAGE - Recombinant Human SIGLEC5 protein (Fc Chimera) (ab221413)
    SDS-PAGE - Recombinant Human SIGLEC5 protein (Fc Chimera) (ab221413)

    SDS-PAGE analysis of reduced ab221413 stained overnight with Coomassie Blue.

    The protein migrates as 90-105 kDa under reducing conditions (SDS-PAGE) due to glycosylation.

References

ab221413 has not yet been referenced specifically in any publications.

Publishing research using ab221413? Please let us know so that we can cite the reference in this datasheet.

Customer reviews and Q&As

Show All Reviews Q&A
Submit a review Submit a question

There are currently no Customer reviews or Questions for ab221413.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com